How Serrapeptase work?
Protein is the main component of most of the fibrous
materials in the body. Once these fibrous materials out-live their purpose or
are over-grown, they start causing serious disease conditions involving
fibrosis. Fibrosis is an abnormal thickening and scarring of connective tissue
caused by infection, injury, surgery or lack of oxygen. Serrapeptase works as an
anti-fibrotic and helps in relieving the conditions in connective tissue
scarring and thickening has occurred.
Serrapeptase, technically called Serratio peptidase, is a
proteolytic enzyme, which means it chops up or digests protein. It is produced
by bacteria in the gut of silkworms, and is used to digest their cocoons. When
this enzyme is isolated and layered with an enteric coating layer in the form
of a tablet, it has been shown to act as anti-inflammatory and pain-blocking
agents, such as aspirin, ibuprofen and other anti-inflammatory drugs (NSAIDs).
What's more, preliminary studies show that Serrapeptase may even help
inhibit plaque build up in arteries, thus preventing atherosclerosis (hardening
of the arteries) and leads a heart attack or stroke. Therefore, like aspirin,
these naturally derived enzymes may work to prevent inflammation,
pain, heart attack and stroke. Unlike aspirin and other over-the-counter (OTC)
NSAIDs, has not been shown Serrapeptase cause ulcers and bleeding in
the stomach.
Serrapeptase is thought to work in three ways:
Serrapeptase has been used in Europe and Asia for over 25 years.
Because the enzyme digests or dissolves all nonliving tissue, including blood
clots, cysts and arterial plaque, it is used to treat a variety of conditions,
including sprains and torn ligaments, swelling after surgery, venous thrombosis
(blood clots in the legs) , ears, nose, ear and throat infections and
atherosclerosis.
Abroad, Serrapeptase is marketed under various names including,
DanzenTM, AniflazymTM and SerraZymeTM. In the U.S., it has been used and
marketed as Serrapeptase since 1997. Pain-relieving and
anti-inflammatory supplement that has anti-clotting activity without the risk
of bleeding in your stomach? Sounds too good to be true? Let's look at the
research.
The data When searching PubMed for Serrapeptase, can be found
nearly 40 clinical trials, most of which are of European or Asian scientists,
including Serrapeptase has not hit the mainstream in the U.S. trials
in general, conclude that Serrapeptase can have tremendous benefits.
For example, a multicenter, double-blind, randomized trial done at the
Institute of Clinical Otorhinolaryngology at the University of Naples in Italy,
found that Serrapeptase acted as an effective anti-inflammatory
improve ear, nose and throat disorders, and supplements reduce pain. The study,
which used 193 people and lasted eight days, also found that Serrapeptase
caused no significant side effects. 2
Another multicenter, double-blind study, published in the journal,
Pharmatherapeutica, found that Serrapeptase reduces inflammation in
patients undergoing surgery for the treatment of empyema (collection of pus in
the cavity between the lung and the membrane that surrounds it). This study
included 174 patients and showed no adverse side effects. Another
study on postoperative swelling and made by German scientists showed that
patients who underwent ankle surgery and receiving Serrapeptase had a
50% reduction in inflammation than in patients not receiving Serrapeptase
had no reduction in inflammation. Patients taking the supplement were also
relieved of any pain during the tenth day after the operation. 3
Small studies (in 20 patients) done over a period of six weeks and published
in the Journal of the Association of Physicians of India, found that Serrapeptase
can help improve carpal tunnel syndrome. No significant side effects
were observed. 4
Another treatment involves using Serrapeptase fibrocystic breast
disease. In one double-blind study published in the Singapore Medical Journal,
70 women with breast engorgement randomly divided into treatment and placebo
groups. There was more to reduce breast pain and inflammation in women
receiving Serrapeptase, but it was for women who did not receive
supplements. Again, were no side effects. 5
As for the heart benefits of Serrapeptase, the evidence supporting
this is largely anecdotal and based largely on the research of the late Hans A.
Nieper, MD, as a Satanist by Inter Hannover, Germany, which is widely known and
also considered anti establishment. He studied the effects of
Serrapeptase on plaque accumulation in the arteries. A book of Dr.
Nieper's work, entitled, The Curious Man: The Life and works of Dr.
Hans Nieper (Avery Penguin Putnam, December 1998), provides insight into
learning. An Italian study conducted at the University of Naples in the
department of vascular surgery, showed that Serrapeptase was effective
and well tolerated in patients with inflammatory venous disease. But more
research is needed to accurately and specifically determine the effect of Serrapeptase
can have on cardiovascular health.
SafetyAs with each topic one consumes (from food to pills), there is
potential for danger. Just because something is "natural"
does not mean that it is automatically safe. Certainly running and the recent
controversy over the regulation of nutritional supplements to indicate that one
has to be cautious and informed when any supplement. Although naturally
derived supplements can be beneficial and safe, they can also be harmful if
used carelessly or without help from a doctor or nurse.
That said, Serrapeptase is a powerful enzyme that comes with a Few
Cautions. The elderly who use the product over a long period of time,
gastrointestinal irritation may occur, but this is rare. There is also an
increased risk of lung infection and pneumonia when using Serrapeptase.
This is rare (as evidenced by some individual letters to the editor in medical
journals) 6 but is a possibility because Serrapeptase thins mucus
secretion, which can lead to complications in the lungs if the person has a
history of lung problems. Also note that studies with Serrapeptase
reach over a long period of time. The long-term effects of this
supplement has not yet been determined.
DosageThe recommended dose is 10 mg to 30 mg per day. Preventive, 10 mg. For
rheumatoid arthritis, sinusitis, fibrocystic breast, bronchitis and
cardiovascular problems, 20 mg. For pain, start with 10 mg daily and work up to
20 mg if needed. Injury, trauma or post-surgical recovery, take 30 mg a day for
two days, then go down to 20 mg a day until the swelling and pain subside.
Be sure to take Serrapeptase on an empty stomach, which means that Serrapeptase
should be taken at least two hours after eating, and no one can eat for half an
hour after taking Serrapeptase.
It is important to note that not all Serrapeptase products are
created equal. Enzyme activity is measured in units and clinical studies are
based on the ratio of 10 mg of Serrapeptase level 20, 000 units of
activity. When purchasing a product to make sure that the proportion of units
of mg to 10 mg per 20, 000 units, or 5 mg of 10, 000 units, and so on. The
average dose is 20 mg, or 40, 000 units.
Conclusion despites the fact that it has not been advertised in this
publication, Life Extension members have used Serrapeptase
for years. It is largely through word of mouth that this supplement has become
so popular. While more research is clearly needed to fully substantiate the
alleged benefits, Serrapeptase has become a popular low-cost addition
to reducing many BMD.
Serrapeptase is made by a company called Cardiovascular Research
Ltd and is primarily sold to patients by other medical doctors. A bottle of 100
5mg tablets retail for $ 18 00 Life Extension members pay $ 13. 50 If
four bottles are purchased, the cost is reduced to $ 12. 56 on a bottle.
To order Serrappeptase Book online or call 1-800-544-4440. eferences.
1 Harris Interactive Over-The-Counter Analgesic Study conducted by the
National Consumers League. January 30, 2003. Chairman of the Harris Poll, New
York, NY: Humphrey Taylor. Contact: www. Harris Interactive. com and www.
nclnet. Org.
2 A Mazzone, et al. Evaluation of serratia peptidase in acute or chronic
inflammation of otorhinolaryngology pathology: A multicentre, double-blind,
randomized trial versus placebo. J Int Med Res. ; 1990; 18 (5), 379-88.
3 Tachibana M, et al. A muti-center, double-blind study of serrapeptase
versus placebo in post antrotomy stomatitis. Pharmatherapeutica; 1984, 3 (8),
526-30.
4 Panagariya A, Sharma AK. A preliminary study of serratiopeptidase in
patients with carpal tunnel syndrome. J Assoc Physicians India; 1999; 47 (12),
1170-1172.
5 Kee WH, et al. The treatment of breast engorgement with Serrapeptase
(Danze): a randomized double-blind controlled study. Singapore Med J. ; 1989 30
(1), 48-54.
6 Sasaki S, et al. Serrapeptase-induced lung injury manifesting as
acute eosiniphilic pneumonia. Nihon Kokyuki Gakkai Zasshi. 2000; 38 (7), 540-4.
http://encyclopedia2013.biz/Serrapeptase_side_effects_384/3/
Additional Info
What Are Systemic Enzymes And What Do They Do?
The word "systemic" means body wide. Systemic
enzymes help maintain homeostasis, or balance within the body. They play a
major role in all metabolic and physiological responses in the body. They are
necessary in the maintenance of good health! But, lets start first by asking
the question, what is an enzyme?
An enzyme is a biocatalyst - meaning something that makes
something else work, or, work faster. Chemical reactions are generally slow and
enzymes speed them up. (As slow as sap running down a tree in winter). For life
to manifest as we know it, enzymes are essential to speed up the reactions. We
have roughly some 3,000 enzymes in our bodies, which results in over 7,000
enzymatic reactions. Most of these enzymes are derived or created from what we
think of as the protein digesting enzymes. While digestion is an important part
of what enzymes do, it's almost the absolute last function. First and foremost
these body wide proteolytic (protein eating) enzymes have the following
actions:
Natural Anti-Inflammatory. They are the first line of
defense against inflammation. (1,2,3). Inflammation is a reaction created by
the immune system as an irritation. Let's say you have an injured right knee.
The immune system sensing the irritation from the knee creates a protein chain
called a Circulating Immune Complex (CIC for short), tagged specifically for
that right knee. (The Nobel Prize in biology was won in 1999 by a scientist who
discovered this tagging mechanism). This CIC floats down to the right knee and
causes pain; redness and swelling these are the classic earmarks for
inflammation. This at first is a beneficial reaction; it warns us that a part
of ourselves is hurt and needs attention. But, inflammation is self-perpetuating
itself creating an irritation that the body makes CIC's to in response!
Aspirin, Ibuprofen, Celebrex, Vioxx and the rest of the Non
Steroidal Anti Inflammatory Drugs all work by keeping the body from making all
CIC's. This ignores the fact that some CIC's are vital to life, like those that
maintain the lining of the intestine, and those that keep the kidneys
functioning! Not to mention the fact that the NSAID's, along with
acetaminophen, are highly toxic to the liver. Every year 20,000 Americans die from
these over the counter drugs and another 100,000 will wind up in the hospital
with liver damage, kidney damage or bleeding intestines from the side effects
of these drugs. (4,5).
Systemic enzymes on the other hand are perfectly safe and
free of dangerous side effects. They have no LD-50, or toxic dose. (6). Best of
all systemic enzymes can tell the difference between the good CIC's and the bad
ones because hydrolytic enzymes are lock and key mechanisms and their
"teeth" will only fit over the bad CIC's. So instead of preventing
the creation of all CIC's, systemic enzymes just "eat" the bad ones
and in so doing lower inflammation everywhere. With that, pain is lowered also.
Anti-Fibrosis. Enzymes eat scar tissue and fibrosis. (7).
Fibrosis is scar tissue and most doctors learn in anatomy that it is fibrosis
that eventually kills us all. Let me explain. As we age, which starts at 27, we
have a diminishing of the bodies' output of enzymes. This is because we make a
finite amount of enzymes in a lifetime and we use up a good deal of them by the
time we are 27. At that point the body knows that if it keeps up that rate of
consumption we'll run out of enzymes and be dead by the time we reach our 40's.
(Cystic Fibrosis patients who have virtually no enzyme production to speak of,
even as children usually don't make it past their 20's before they die of the
restriction and shrinkage in the lungs from the formation of fibrosis or scar
tissue).
So our body in it's wisdom begins to dole out our enzymes
with an eyedropper instead of with a tablespoon; as a result the repair
mechanism of the body goes out of balance and has nothing to reduce the over
abundance of fibrin it deposits in nearly every thing from simple cuts, to the
inside of our internal organs and blood vessels. This is when most women begin
to develop things like fibrocystic breast disease, uterine fibroids,
endometriosis, and we all grow arterial sclerotic (meaning scar tissue) plaque,
and have fibrin beginning to spider web its way inside of our internal organs
reducing their size and function over time. This is why as we age our wounds
heal with thicker, less pliable, weaker and very visible scars.
If we replace the lost enzymes we can control and reduce the
amount of scar tissue and fibrosis our bodies have. As physicians in the US are
now discovering, even old scar tissue can be "eaten away" from
surgical wounds, pulmonary fibrosis, kidney fibrosis and even keloids years
after their formation. Medical doctors in Europe and Asia have known this and have
used orally administered enzymes for these situations for over 40 years!
Blood Cleansing. The blood is not only the river of life; it
is also the river through which the cells and organs dispose of their garbage
and dead material. Enzymes improve circulation by eating the excess fibrin that
causes blood to sometimes get as thick as catsup or yogurt, creating the
perfect environment for the formation of clots. All of this material is
supposed to be cleared by the liver on its "first pass", or the first
time it goes through but given the sluggish and near toxic or toxic states of
everyone's liver these days that seldom happens. So the sludge remains in the
blood waiting for the liver to have enough free working space and enough
enzymes to clean the trash out of the blood. This can take days, and in some
cases, weeks! (8).
When systemic enzymes are taken, they stand ready in the
blood and take the strain off of the liver by:
1. Cleaning excess fibrin from the blood and reducing the
stickiness of blood cells. These two actions minimize the leading causes of
stroke and heart attack causing blood clots. (8). 2. Breaking dead material
down small enough that it can immediately pass into the bowel. (8). 3. Cleanse
the FC receptors on the white blood cells improving their function and
availability to fight off infection. (9).
And here we come to the only warning we have to give
concerning the use of GemZyme or any other systemic enzyme - don't use the
product if you are a hemophiliac or are on prescription blood thinners like
Coumadin, Heparin and Plavix, without direct medical supervision. The enzymes
cause the drugs to work better so there is the possibility of thinning the
blood too much.
Immune System Modulating. Enzymes are adaptogenic seeking to
restore a steady state to the body. (9). When the immune system is running low
we become susceptible to infectious disease, when it's cranked up too high then
the system creates antibodies that attack it's own tissues as are seen in the
auto immune diseases of MS, Rheumatoid Arthritis, and Lupus. Here the enzymes
will tone down immune function and eat away at the antibodies the immune system
is making to attack its bodies own tissue.
Virus Fighting. Viruses harm us by replicating in our
bodies. To do this a virus must bond itself to the DNA in our cells through the
medium of its exterior protein cell wall. Anything that disrupts that cell wall
inhibits the ability of viral replication by rendering individual viruses
inert. (10,11). Systemic enzymes can tell the difference between the proteins
that are supposed to be in your body and those that are foreign or not supposed
to be there, (again the enzyme lock and key mechanism). GemZyme has the
strongest protein eating effect of any enzyme due to its Serrapeptase content
and can be of help in combating viruses.
One note: many in the States have learned in school that
enzymes are too big a protein to be absorbed through the gut. The pioneering
research done in the US by Dr. Max Wolf (MD & PhD x7) at Columbia
University in the 40's through the 70's has not made it to the awareness of
most doctors. There are currently over 200 peer reviewed research articles
dealing with the absorption, utilization and therapeutic action of orally
administered systemic enzymes. A search through Pub Med using the key words:
Serrapeptase, Papain, Bromelain, Trypsin, Chymo trypsin, Nattokinase and
systemic enzyme will yield some of the extensive work. Systemic enzymes now
have a 4-decade plus history of widespread medical use in central Europe and
Japan.
GemZyme with its Serrapeptase based blend of enzymes is the
strongest and fastest working systemic enzyme on the planet with research to
prove it.).
References: 1) Carroll A., R.: Clinical examination of an
enzymatic anti-inflammatory agent in emergency surgery. Arztl. Praxis 24
(1972), 2307. 2) Mazzone A, et al.: Evaluation of Serratia peptidase in acute
or chronic inflammation of otorhinolaryngology pathology: a multicentre, double
blind, randomized trial versus placebo. J Int Med Res. 1990; 18(5):379-88. 3)
Kee W., H. Tan S, L., Lee V. Salmon Y. M.: The treatment of breast engorgement
with Serrapeptase: a randomized double blind controlled trial. Singapore Med J.
1989:30(l):48-54. 4) Celebrex article Wall Street Journal 19 April 1999. 5) No
author listed: Regular Use of Pain Relievers Can Have Dangerous Results.
Kaleidoscope Interactive News, American Medical Association media briefing.
July 24, 1997. 6) Enzymes ñ A Drug of the Future, Prof. Heinrich Wrba MD and
Otto Pecher MD. Published 1993 Eco Med. 7) Kakinumu A. et al.: Regression of
fibrinolysis in scalded rats by administration of serrapeptase. Biochem.
Pharmacol. 31:2861-2866,1982. 8) Ernst E., Matrai A.: Oral Therapy with
proteolytic enzymes for modifying blood rheology. Klin Wschr. 65 (1987), 994.
9) Kunze R., Ransberger K., et at: Humoral immunomodulatory capasity of
proteases in immune complex decomposition and formation. First International
symposium on combination therapies, Washington, DC, 1991. 10) Jager H.: Hydrolytic
Enzymes in the therapy of HIV disease. Zeitschr. Allgemeinmed., 19 (1990), 160.
11) Bartsch W.: The treatment of herpes zoster using proteolytic enzymes. Der
Informierte Arzt. 2 (1974), 424-429. © Copyright 1999-2004 Wholelistic
Knowledge Educators, LLC and its licensors.
Serrapeptase: Enzyme Fights Inflammation
Our bodies have a love-hate relationship with inflammation. On the one hand,
inflammation is a natural response, necessary to protect the body from invading
organisms. On the other hand, inflammation can limit joint function, and
destroy bone, cartilage and other articular structures.
An elusive goal of scientists and physicians has been to find a
side-effect-free substance to reduce the pain and inflammation associated with
fibrocystic breast disease, rheumatoid arthritis, idiopathic edema, carpal
tunnel syndrome and post-operative swelling. It appears that the search may be
nearing an end, thanks to an enzyme Serrapeptase produced by the larval form of
the silk moth.
Serrapeptase is proving to be a superior alternative to the non-steroidal
anti-inflammatory agents (NSAIDs) traditionally used to treat rheumatoid
arthritis and osteoarthritis. Its uses have also been extended to the treatment
of chronic sinusitis and postoperative inflammation, and some researchers
believe the substance can play an important role in arterial plaque prevention
and removal.
Harmful Effects of NSAIDs
NSAIDs, which include aspirin, ibuprofen, salicylates, and naproxen, are among
the most commonly prescribed medications for inflammation resulting from
rheumatoid arthritis, joint conditions, osteoarthritis, gouty arthritis, joint
and muscle discomfort associated with systemic lupus erythematosus, and other
musculoskeletal disorders. (1) In some cases, this over reliance on NSAIDs has
proved deadly. Annually, 76,000 people are hospitalized from NSAID-induced
gastrointestinal complications. The American Medical Association estimates that
from 50-80 percent of those hospitalized for gastrointestinal bleeding are taking
some form of NSAIDs. At this stage in the medication-induced bleeding, there is
a ten percent chance of fatality. (2)
NSAIDs lethal effects result from the inhibition of the biosynthesis of
prostaglandins. NSAIDs block Cyclo-oxygenase, the enzyme responsible for
catalyzing the reactions of arachidonic acid to endoperoxide compounds. This
process results in the inhibition of gastric prostaglandin E, a hormone that
protects the lining of the stomach from acid. After prolonged and frequent
ingestion of NSAIDs, the stomach remains defenseless and at increased
susceptibility to ulcers. (3-4) If an ulcer erodes into a blood vessel,
bleeding results. An ulcer can destroy part of the stomach and duodenal walls,
leaving a gap that requires immediate surgery.
In one study, 1,826 osteoarthritis or rheumatoid arthritis patients who had
been taking NSAIDs for six months or more and who had been unable to tolerate
continuous NSAID use because of adverse gastrointestinal symptoms were examined
endoscopically for gastroduodenal lesions and ulcers. Clinically significant
gastroduodenal lesions were found in 37.1 percent of the patients. Of those, 24
percent had ulcers. The prevalence of gastroduodenal ulcers increased with age,
duration of osteoarthritis, and duration of current NSAID use. The authors of
the study wrote: "These results provide further endoscopic confirmation of
the association between NSAID use and gastroduodenal lesions and ulcers and
support the contention that safer treatment alternatives to conventional NSAIDs
are required."(5)
Serrapeptase: A Natural Anti-Inflammatory
Serrapeptase, also known as Serratia peptidase, is a proteolytic enzyme
isolated from the non-pathogenic Enterobacteria Serratia E15. When consumed in
unprotected tablets or capsules, the enzyme is destroyed by acid in the
stomach. However, enterically coated tablets enable the enzyme to pass through
the stomach unchanged, and be absorbed in the intestine. Serrapeptase is found
in negligible amounts in the urine, suggesting that it is transported directly
from the intestine into the bloodstream. (15,16) Clinical studies show that
Serrapeptase induces fibrinolytic, anti-inflammatory and anti-edemic (prevents
swelling and fluid retention) activity in a number of tissues, and that its
anti-inflammatory effects are superior to other proteolytic enzymes. (18)
Besides reducing inflammation, one of Serrapeptase's most profound benefits is
reduction of pain, due to its ability to block the release of pain-inducing
amines from inflamed tissues. (18) Physicians throughout Europe and Asia have
recognized the anti-inflammatory and pain-blocking benefits of this naturally
occurring substance and are using it in treatment as an alternative to
salicylates, ibuprofen and other NSAIDs. (19)
In Germany and other European countries, Serrapeptase is a common treatment for
inflammatory and traumatic swellings, and much of the research that exists on
this substance is of European origin. One double-blind study was conducted by
German researchers to determine the effect of Serrapeptase on post-operative
swelling and pain. This study involved sixty-six patients who were treated
surgically for fresh rupture of the lateral collateral ligament of the knee. On
the third post-operative day, the group receiving Serrapeptase exhibited a 50
percent reduction of swelling, compared to the controls. The patients receiving
Serrapeptase also became more rapidly pain-free than the controls, and by the
tenth day, the pain had disappeared completely. (20)
Cystic Breast Disease
Serrapeptase has also been used in the successful treatment of fibrocystic
breast disease. In a double-blind study, 70 patients complaining of breast
engorgement randomly were divided into a treatment group and a placebo group.
Serrapeptase was superior to the placebo for improvement of breast pain, breast
swelling and induration (firmness). 85.7 percent of the patients receiving Serrapeptase
reported moderate to marked improvement. No adverse reactions to Serrapeptase
were reported and the researchers concluded, "Serrapeptase is a safe and
effective method for the treatment of breast engorgement.(21, 19)
Serrapeptase and Sinusitis
Due to its inflammatory properties, Serrapeptase has been shown in clinical
studies to benefit chronic sinusitis sufferers. In this condition, the mucus in
patients' nasal cavities is thickened and hyper secreted. This thickening
causes mucus to be expelled less frequently. Japanese researchers evaluated the
effects of Serratiopeptidase (30 mg/day orally for four weeks) on the
elasticity and viscosity of the nasal mucus in adult patients with chronic
sinusitis. Serratiopeptidase reduced the viscosity of the mucus, improving the
elimination of bronchopulmonary secretions. (23)
Other clinical trials support Serrapeptase's ability to relieve the problems
associated with chronic sinusitis. In one study, 140 patients with acute or
chronic ear, nose and throat pathologies were evaluated with either a placebo
or the active Serratia peptidase. Patients taking the Serrapeptase experienced
a significant reduction in severity of pain, amount of secretion, purulence of
secretions, difficulty in swallowing, nasal dysphonia, nasal obstruction,
anosmia, and body temperature after three to four days and at the end of
treatment. Patients suffering from laryngitis, catarrhal rhinopharyngitis and
sinusitis who were treated with Serrapeptase experienced a significant and rapid
improvement of symptoms after 3-4 days. Physicians assessed efficacy of
treatment as excellent or good for 97.3 percent of patients treated with
Serrapeptase compared with only 21.9 percent of those treated with a placebo.
(24)
Respiratory diseases are characterized by increased production of a more dense
mucus modified in viscosity and elasticity. Traditionally, in respiratory
diseases, muco-active drugs are prescribed to reestablish the physicochemical
characteristics of the mucus in order to restore respiratory function. Some of
these drugs, however, cause a functional depletion of mucus, whereas
Serrapeptase alters the elasticity of mucus without depleting it. (25,10)
A powerful agent by itself, Serrapeptase teamed with antibiotics delivers
increased concentrations of the antimicrobial agent to the site of the
infection. Bacteria often endure a process called biofilm formation, which
results in resistance to antimicrobial agents. In an attempt to prevent this
bacterial immunity, researchers have experimented with various means of
inhibiting biofilm-embedded bacteria. Their search may have ended with
Serrapeptase. One study conducted by Italian researchers suggests that
proteolytic enzymes could significantly enhance the activities of antibiotics
against biofilms. Antibiotic susceptibility tests showed that Serratiopeptidase
greatly enhances the activity of the antibiotic, Ofloxacin, and that it can
inhibit biofilm formation.(28)
Another double-blind randomized study evaluated the effects of administering
the antibiotic Cephalexin in conjunction with Serrapeptase or a placebo to 93
patients suffering from either perennial rhinitis, chronic rhinitis with
sinusitis or chronic relapsing bronchitis. The Serratia peptidase treated group
experienced significant improvement in rhinorrhea, nasal stuffiness, coryza and
improvement of the para-nasal sinus shadows. (24)
Researchers witnessed equally impressive results in the treatment of infections
in lung cancer patients undergoing thoracotomy. Serrapeptase and Cefotiam, an
antibiotic with a broad spectrum of activity against both Gram-positive and
Gram-negative microorganisms, were administered to 35 thoracotomy patients with
lung cancer. The patients were divided into two groups. A single dose of
Cefotiam was administered to the 17 subjects in Group I. The 18 subjects in
Group II received a combination of Cefotiam and Serrapeptase. The level of the
antibiotic in the tissues versus the blood was significantly higher in the
Serrapeptase group than the single dose group. (22)
Cardiovascular Implications
Hans A. Nieper, M.D., an internist from Hannover, Germany, studied the effects
of Serrapeptase on plaque accumulations in the arteries. The formation of
plaque involves deposits of fatty substances, cholesterol, cellular waste
products, calcium and fibrin (a clotting material in the blood) on the inner
lining of the arteries. Excessive plaque results in partial or complete
blockage of the blood's flow through an artery, resulting in arteriosclerosis,
or hardening of the arteries, and an ensuing stroke or heart attack. The
evidence to support Serrapeptase's role in preventing plaque build-up is
anecdotal. Still, further studies are called for in this area as Nieper's
research indicated that the protein-dissolving action of Serrapeptase will
gradually break down atherosclerotic plaques. (24)
Conclusion
Regardless of whether Serrapeptase is used for inflammatory diseases or to
prevent plaque build up on the arteries, it is well tolerated. Due to its lack
of side effects and anti-inflammatory capabilities, Serrapeptase is a logical
choice to replace harmful NSAIDs. Thanks to the tiny larvae of the silk moth,
researchers have taken a large step toward finding relief for inflammatory
disease sufferers.
Active Ingredients in this Formula Include:
• Protease, Bromelain, Serrapeptase, lipase, Papain, Rutin and Amia.
Recommendation: Take 3 capsules daily, at least 45 minutes before or after
meals or as recommended by your healthcare professional. References 1. Raskin JB.
Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am J Med.
1999; 106 (5B):3S-12S. 2. No author listed. Regular Use of Pain Relievers Can
Have Dangerous Results. Kaleidoscope Interactive News, American Medical
Association media briefing. July 24, 1997. 3. Fung HB, Kirschenbaum, HL.
Selective cyclooxygenase-2 inhibitors for the treatment of arthritis. Clin
Ther. 1999; 21(7):1131-57. 4. Geis GS. Update on clinical developments with
celecoxib, a new specific COX-2 inhibitor: what can we expect? Scand J
Rheumatol Suppl. 1999; 109:31-7. 5. Cheatum DE, Arvanitakis C, Gumpel M, Stead
H, Geis GS. An endoscopic study of gastroduodenal lesions induced by
nonsteroidal anti-inflammatory drugs. Clin Ther. 1999; 21(6):992-1003. 6.
Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A, Bjarnason
I. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut.
1999; 45(3):362-6. 7. Dingle JT. The effects of NSAID on the matrix of human
articular cartilages. Z Rheumatol. 1999; 58(3):125-9. 8. Murphy PJ, Badia P,
Myers BL, Boecker MR, Wright KP Jr. Nonsteroidal anti-inflammatory drugs affect
normal sleep patterns in humans. Physiol Behav. 1994; 55(6):1063-6. 9. Metz SA,
Robertson RP, Fujimoto WY. Inhibition of prostaglandin E synthesis augments
glucose-induced insulin secretion in cultured pancreas. Diabetes. 1981;
30(7):551-7. 10. Marriott C. Modification in the rheological properties of
mucus by drugs. Adv Exp Med Biol. 1982; 144:75-84. 11. Tokumine F, Sunagawa T,
Shiohira Y, Nakamoto T, Miyazato F, Muto Y. Drug-associated cholelithiasis: a
case of sulindac stone formation and the incorporation of sulindac metabolites
into the gallstones. Am J Gastroenterol. 1999;94(8):2285-8. 12. Jiang HK, Chang
DM. Non-steroidal anti-inflammatory drugs with adverse psychiatric reactions:
five case reports. Clin Rheumatol. 1999;18(4):339-45. 13. Fung HB,
Kirschenbaum, HL. Selective cyclooxygenase-2 inhibitors for the treatment of
arthritis. Clin Ther. 1999; 21(7):1131-57. 14. FDA MedWatch: The FDA Medical
Products Reporting Program. May 12, 1999. FDA Talk Paper. 15. Moriya N, Nakata
M, Nakamura M, Takaoka M, Iwasa S, Kato K, Kakinuma A. Intestinal absorption of
serrapeptase (TSP) in rats. Biotechnol Appl Biochem. 1994; 20(Pt1):101-8. 16.
Miyata, K. Intestinal absorption of Serratia Peptidase. J Appl Biochem.
1980;2:111-16. 17. Perna L. Osservazionl Clniche sui traitamento in osppio
cleco con Serratio peptidasl nella neifre perenna naila ninite cronica
nacutizzata con sinusopattia, nella bronchia cronica nacutizzata. Rlv Pat Clin
Tuberc Penumol. 1985; 56:509-516. 18. Mazzone A, et al. Evaluation of Serratia
peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a
multicentre, double-blind, randomized trial versus placebo. J Int Med Res.
1990; 18(5):379-88. 19. Aso T et al. Breast engorgement and its treatment:
Clinical effects of Danzen an anti- inflammatory enzyme preparation. The world
of Obstetrics and Gynecology (Japanese). 1981; 33:371-9. 20. Esch PM, Gerngross
H, Fabian A. Reduction of postoperative swelling. Objective measurement ofi
swelling of the upper ankle joint in treatment with serrapeptase-a study
(German). Fortschr Med. 1989;107(4):67-8, 71-2. 21. Kee WH, Tan SL, Lee V,
Salmon YM. The treatment of breast engorgement with Serrapeptase (Danzen): a
randomized double-blind controlled trial. Singapore Med J. 1989;30(1):48-54.
22. Koyama A, Mori J, Tokuda H, Waku M, Anno H, Katayama T, Murakami K, Komatsu
H, Hirata M, Arai T, et al. Augmentation by serrapeptase of tissue permeation
by cefotiam (Japanese). Jpn J Antibiot. 1986; 39(3):761-71. 23. Majima Y,
Inagaki M, Hirata K, Takeuchi K, Morishita A, Sakakura Y. The effect of an
orally administered proteolytic enzyme on the elasticity and viscosity of nasal
mucus. Arch Otorhinolaryngol. 1988;244(6):355-9. 24. Brewer Science Library
website. 1999. prospective 25. Tomoda K, and Miyatam K. Some information on the
composition of trachael secretions before and after the administration of
Danzen. Exper Ther. 1972; 477:9-16. 26. Kase Y, et al. A new method for
evaluating mucolytic expectorant activity and its application to two
proteolytic enzymes, serratiopeptidase and seaprose. Arznelrnitteltorachung.
1982; 32:374-378. 28. Selan L, Berlutti F, Passariello C, Comodi-Ballanti MR,
Thaller MC. Proteolytic enzymes: a new treatment strategy for prosthetic
infections? Antimicrob Agents Chemother. 1993; 37(12):2618-21. The above
statements have not been evaluated by the FDA. This product is not intended to
diagnose, treat, cure, or prevent any diseases
http://www.gematria.com/ProductDetails.asp?ProductCode=46-90-AS
